TY - JOUR
T1 - Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
AU - Gianni, Luca
AU - Baselga, José
AU - Eiermann, Wolfgang
AU - Porta, Vicente Guillem
AU - Semiglazov, Vladimir
AU - Lluch, Aña
AU - Zambetti, Milvia
AU - Sabadell, Dolores
AU - Raab, Günther
AU - Cussac, Antonio Llombart
AU - Bozhok, Alla
AU - Martinez-Agulló, Angel
AU - Greco, Marco
AU - Byakhov, Mikhail
AU - Lopez Lopez, Juan Josè
AU - Mansutti, Mauro
AU - Valagussa, Pinuccia
AU - Bonadonna, Gianni
PY - 2005/12/15
Y1 - 2005/12/15
N2 - Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v. cyclophosphamide, methotrexate, and fluorouracil (CMF; doxorubicin → CMF, arm A) could be improved by adding paclitaxel (doxorubicin/paclitaxel → CMF) as adjuvant (arm B) or primary systemic therapy (PST, arm C). We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate. Methods: A total of 1,355 women entered the study. Feasibility and safety were compared in arm A versus arms B plus C. Surgical findings were compared in arms A plus B versus arm C. Results: Grade 3 or 4 National Cancer Institute toxicities were low (
AB - Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v. cyclophosphamide, methotrexate, and fluorouracil (CMF; doxorubicin → CMF, arm A) could be improved by adding paclitaxel (doxorubicin/paclitaxel → CMF) as adjuvant (arm B) or primary systemic therapy (PST, arm C). We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate. Methods: A total of 1,355 women entered the study. Feasibility and safety were compared in arm A versus arms B plus C. Surgical findings were compared in arms A plus B versus arm C. Results: Grade 3 or 4 National Cancer Institute toxicities were low (
UR - http://www.scopus.com/inward/record.url?scp=29344467956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=29344467956&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-0539
DO - 10.1158/1078-0432.CCR-05-0539
M3 - Article
C2 - 16361558
AN - SCOPUS:29344467956
VL - 11
SP - 8715
EP - 8721
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 24
ER -